Background illustration for clinical trials search

Paid Clinical Trials Springfield

Discover 192 paid clinical trials in Springfield, Illinois. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 192

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: Springfield IL, Decatur IL, Effingham IL, Mattoon IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Location: Springfield IL, Decatur IL, Effingham IL, Mattoon IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04269902

Phase3, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for

Acral Lentiginous Melanoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04511013

Phase2, Recruiting

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for

Advanced Lung Non-Small Cell Carcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03191149

Phase2, Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for

Intracranial Meningioma, Recurrent Meningioma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT02523014

Phase2, Recruiting

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

for

Castration-Resistant Prostate Carcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT06470243

Phase3, Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for

Metastatic Renal Cell Carcinoma,

Location: Springfield IL, Decatur IL, Effingham IL, Mattoon IL,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05327686

Phase2, Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05987241

Phase2, Phase3, Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for

Pancreatic Acinar Cell Carcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04858334

Phase2, Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

for

Metastatic Small Intestinal Adenocarcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04205968

Phase2, Recruiting

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

for

Colorectal Cancer, Sarcopenia

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 60+

Code: NCT03998202

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Location: Springfield IL, Chicago IL, Indianapolis IN, Madison WI,

Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06119581

Phase3, Recruiting

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

for

Malignancy

Location: Springfield IL, Decatur IL, Canton IL, Normal IL,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 0+

Code: NCT04242095

Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for

Mantle Cell Lymphoma

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 60+

Code: NCT05976763

Phase3, Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

for

Smoldering Plasma Cell Myeloma

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 18+

Code: NCT03937635

Phase3, Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for

Locally Advanced Lung Non-Small Cell Carcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05624996

Phase3, Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Springfield IL, Decatur IL, Pekin IL, Canton IL,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642572

Phase2, Recruiting

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for

Renal Pelvis and Ureter Urothelial Carcinoma

Location: Springfield IL, Decatur IL, Effingham IL, Mattoon IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04628767

Phase2, Phase3, Recruiting

Paid Clinical Trials Springfield

Filter results

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Interested in new trials?

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer